Clinical manifestations and treatment modalities in herpes simplex virus of the ocular anterior segment

International Ophthalmology Clinics

Volumn 44, Issue 3, 2004, Pages 103-133

  Khan, Bilal Faiz ^a   Pavan Langston, Deborah ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA2A INTERFERON; ANTIBIOTIC AGENT; ANTIGLAUCOMA AGENT; ANTIVIRUS AGENT; ARTIFICIAL TEAR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYANOACRYLATE; CYCLOPLEGIC AGENT; DEXAMETHASONE; FAMCICLOVIR; GANCICLOVIR; GLUCOCORTICOID; HOMATROPINE; IDOXURIDINE; LACTASE; PHOSPHATE; PLACEBO; PREDNISOLONE; PREDNISOLONE 21 PHOSPHATE; PREDNISONE ACETATE; SCOPOLAMINE; TRIFLURIDINE; VALACICLOVIR; VIDARABINE;

ALLERGIC BLEPHARODERMATITIS; ANTERIOR EYE SEGMENT; ANTERIOR SEGMENT ISCHEMIA; BLEPHARITIS; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVITIS; CORNEA STROMA; CORNEA TRANSPLANTATION; CORNEA ULCER; DIARRHEA; DRUG COST; DRUG METABOLISM; EYE INFECTION; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEMOLYTIC UREMIC SYNDROME; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HUMAN; IMMUNE DEFICIENCY; IRIDOCYCLITIS; IRITIS; ISCHEMIA; LACRIMAL DUCT OCCLUSION; NONHUMAN; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; PUNCTATE KERATITIS; REVIEW; SIDE EFFECT; SKIN ALLERGY; SKIN DEFECT; SKIN ULCER; SOFT CONTACT LENS; SUPERFICIAL PUNCTATE KERATITIS; THROMBOCYTOPENIC PURPURA; TOXIC EPITHELIAL ULCER; TROPHIC ULCER; VIRAL CONJUNCTIVITIS; VIRUS REACTIVATION; WOUND HEALING IMPAIRMENT;

ANTERIOR EYE SEGMENT; ANTIVIRAL AGENTS; EYE INFECTIONS, VIRAL; HERPES SIMPLEX; HUMANS; SIMPLEXVIRUS; VIRUS ACTIVATION;

EID: 3242663234     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200404430-00012     Document Type: Review

References (188)

1. Cobo M. Ocular herpes simplex infections. Mayo Clin Proc. 1988;63:1154.
2. Liesegang T, Melton JI, Daly P, et al. Epidemiology of ocular herpes simplex: incidence in Rochester, MN 1950-1982. Arch Ophthalmol. 1989;107:1160-1166.
3. Pavan-Langston D. Herpetic infections. In: Smolin G, Thoft R, eds. The Cornea. 3rd ed. Boston, MA: Little Brown; 1994:183-214.
4. Pavan-Langston D. Viral disease of the cornea and external eye. In: Albert D, Jakobiec F, eds. Principles And Practice Of Ophthalmology. Philadelphia, PA: W.B. Saunders; 2000:846-892.
5. Pavan-Langston D. Major ocular viral infections: herpes simplex, adenovirus, Epstein Barr virus, pox. In: Galasso G, Megan T, Whitley R, eds. Antiviral Agents and Viral Diseases of Man. 4th ed. New York, NY: Raven Press; 1997.
6. Pepose J, Leib D, Stuart M, et al. Herpes simplex virus diseases: anterior segment of the eye. In: Pepose J, Holland G, Wilhelmus K, eds. Ocular Infection and Immunity. St. Louis, MO: Mosby; 1996:905-932.
7. World Health Organization. Prevention and control of herpes virus diseases. Part 1. Clinical and laboratory diagnosis and chemotherapy. A WHO meeting. Bull World Health Organ. 1985;63:185-201.
8. Kaye SB, Bonshek R, Hart CA. Human herpes virus in the cornea. Br J Ophthalmol. 2000;84:563-571.
9. Straus SE, Rooney JF, Sever LJ. Herpes simplex virus infection: biology, treatment and prevention. Ann Intern Med. 1985;103:404.
10. Wilhelmus R, Coster D, Donovan H, et al. Prognostic indicators of herpetic keratitis: analysis of a five year observation period after corneal ulceration. Arch Ophth. 1981;91:1578.
11. Whitley R, Nahmias A, Visintine A. The natural history of herpes simplex virus infection of mother and newborn. Pediatrics. 1980;4:489.
12. HEDS. Psychological stress and other potential triggers for recurrences of herpes simples virus eye infections. Arch Ophthalmol. 2000;118:1617-1625.
13. Ventura L, Dix R. Viability of herpes simplex virus type I on the applanation tonometer. Am J Ophthalmol. 1987;103:48.
14. Azazi M, Gunilla M, Forsgren M. Late ophthalmologic manifestations of neonatal herpes simplex virus infection. Am J Ophthalmol. 1990;109:1-7.
15. Nahmias A, Roisman B. Infection with herpes simplex viruses I & II. Part III. N Engl J Med. 1973:289:781.
16. Buddingh G, Schrum D, Lanier J, et al. Studies on the natural history of herpes simplex infections. Pediatrics. 1953;11:595.
17. Smith I, Peutherer J, MacCallum F. The incidence of herpes virus hominus antibody in the population. J Hyg (Camb). 1967;65:395.
18. Liesegang T. Ocular herpes simplex infection: pathogenesis and current therapy. Mayo Clin Proc. 1988;63:1092.
19. Hyndiuk R, Classer D. Herpes simplex keratitis. In: Tabbara K, Hyndiuk R, eds. Infections of the Eye. 2nd ed. Boston, MA: Little Brown & Co.; 1996:361-386.
20. Bell D, Holman R, Pavan-Langston D. Epidemiologic aspect of herpes simplex keratitis. Ann Ophthalmol. 1982;14:421.
21. Shuster J, Kaufman H, Nesburn A. Statistical analysis of the rate of recurrence of herpes virus ocular epithelial disease. Am J Ophthalmol. 1981;91:328.
22. Wilhelmus K, Coster D, Donovan H, et al. Prognostic indicators of herpetic keratitis: analysis of a five year observation period after corneal ulceration. Arch Ophthalmol. 1981;91:1578.
23. Bastian F, Rabson A, Yee C, et al. Herpes virus hominus: isolation from human trigeminal ganglion. Science. 1972;178:306.
24. Baringer J, Swoveland P. Recovery of herpes simplex virus from human trigeminal ganglions. N Engl J Med. 1973;288:648.
25. Labetoulle M, Maillet S, Lafay F. HSV 1 latency sites after inoculation in the lip: assessment of their localization and connections to the eye. Invest Ophthalmol Vis Sci. 2003;44:217-225.
26. Claoue C, Hill T, Blyth W, et al. Clinical findings after zosteriform spread of herpes simplex virus to the eye of the mouse. Curr Eye Res. 1987;6:281.
27. Kaye S, Madan N, Dowd T, et al. Ocular herpes virus shedding. Br J Ophthalmol. 1990;74:114.
28. Yamamoto S, Shimomura Y, Kinoshita S, et al. Detection of herpes simplex virus DNA in human tear film by the polymerase chain reaction. Am J Ophthalmol. 1994;117:160-163.
29. Kaye S, Lynas C, Patterson A, et al. Evidence for herpes simplex viral latency in the human cornea. Br J Ophthalmol. 1991;75:195-200.
30. Asbell P, Centifanto-Fitzgerald Y, Chandler J, et al. Analysis of viral DNA in isolates from patients with recurrent herpetic keratitis. Invest Ophthalmol Vis Sci. 1984;25:951.
31. Pavan-Langston D, Rong B, Dunkel E. Extraneuronal herpetic latency: animal and human corneal studies. Acta Ophthalmol. 1989;67(suppl 192):135-141.
32. Rong B, Pavan-Langston D, Weng Q, et al. Detection of HSV thymidine kinase and latency-associated transcript gene expression in human herpetic corneas by polymerase chain reaction. Invest Ophthalmol Vis Sci. 1991;32:1808.
33. Hedshed SG. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med. 1998;339:300-341.
34. Sabbaga E, Pavan-Langston D, Bean K, et al. Detection of HSV nucleic acid sequences in the cornea during acute and latent ocular disease. Exp Eye Res. 1988;47:545.
35. Zheng X. Reactivation and donor host transmission of herpes simplex virus after corneal transplantation. Cornea. 2002;21(suppl 7):S90-S93.
36. Remeijer L, Maertzdorf J, Verjans GM, et al. Corneal herpes simplex virus type1 superinfection in patients with recrudescent herpetic keratitis. Invest Ophthalmol Vis Sci. 2002;43:358-363.
37. Kaufman H, Centifanto-Fitzgerald Y, et al. Herpes simplex keratitis. Ophthalmol. 1983;90:700.
38. Spear P. Glycoprotein specified by herpes simplex viruses. In: Roadman B, ed. The Herpesviruses. New York, NY: Plenum Press; 1985:315.
39. Tullo A, Cupes D, Klapper P, et al. Analysis of glycoproteins expressed by isolates of herpes simplex virus causing different forms of keratitis in man. Cuur Eye Res. 1987;6:33-38.
40. Kaufman H, Brown D, Ellison E. Recurrent herpes in the rabbit and man. Science. 1967;156:1628.
41. Openshaw H, Asher L, Wohlenberg C, et al. Acute and latent infection of sensory ganglia with herpes simplex virus: immune control and virus reactivation. J Gen Virol. 1979;44:205.
42. Centifanto Y, Little J, Kaufman H. Relationship between virus chemotherapy, secretory antibody formation and recurrent herpetic disease. Ann N Y Acad Sci. 1973;173:649.
43. Hammer H, Dobozy A. Cell mediated immunity to herpes virus type I in patients with recurrent corneal Herpes simplex. Acta Ophthalmol. 1980;58:161.
44. Meyers R, Chitjian P. Immunology of herpes virus infection: immunity to herpes simplex virus in eye infections. Surv Ophthalmol. 1976;21:194.
45. Dawson C, Togni B, Moore T Jr. Structural changes in chronic herpetic keratitis: studied by light and electron microscopy. Arch Ophthalmol. 1968;79:740.
46. Easty D, Shimeld C, Claoue C, et al. Herpes simplex virus isolation in chronic stromal keratitis: human and laboratory studies. Curr Eye Res. 1987;6:69.
47. Hogan M. Corneal transplantation in the treatment of herpetic disease of the cornea. Am J Ophthalmol. 1957;43:147.
48. Holbach L, Font R, Naumann G. Herpes simplex stromal and endothelial keratitis. Ophthalmol. 1990;97:722.
49. Pavan-Langston D, Nesburn AB. The chronology of primary herpes simplex infection of the eye and adnexal glands. Arch Ophthalmol. 1968;80:258-264.
50. Dunkel EC, Pavan-Langston D, Fitzpatrick K, et al. Rapid detection of herpes simplex virus (HSV) antigen on human ocular infections. Curr Eye Res. 1988;7:661-666.
51. Brik D, Dunkel E, Pavan-Langston D. Persistent herpes simplex virus in the corneal stroma despite topical and systemic antiviral therapy. Arch Ophthalmol. 1994;111:522-527.
52. HEDS: predictors of recurrent herpes simplex virus keratitis. Cornea. 2001;20:123-128.
53. Lairson DR, Begley CE, Wilhelmus KR. Prevention of herpes simplex virus eye disease: a cost effectiveness analysis. Arch Ophthalmol. 2003;121:108-112.
54. Kowlaski R, Karenchak LM, Shah C, et al. ELVIS: a new 24-hour culture test for detecting herpes simplex virus from ocular samples. Arch Ophthal. 2002;120:960-962.
55. Yamamoto S, Pavan-Langston D, Kinoshita S. Detecting herpes virus DNA in uveitis using the polymerase chain reaction. Br J Ophthalmol. 1996;80:465-468.
56. Balfour HJ. Antiviral drugs. N Engl J Med. 1999;340:1255-1268.
57. Pavan-Langston D, Dunkel E. Ocular pharmacology of antiviral drugs. In: Tasman W, Jaeger E, eds. Duane's Foundations of Clinical Ophthalmology. Philadelphia, PA: Lippencott-Raven; 1995:1-24.
58. O'Brien W. Antiviral agents. In: Tabbara K, Hyndiuk R, eds. Infections of the Eye. 2nd ed. Boston, MA: Little Brown & Co.; 1996:269-280.
59. Snoeck R, DeClercq E. Treatment of herpes simplex virus infections. Infections Med. 1999;16:249-265.
60. Teich SA, Cheung TW, Friedman AH. Systemic antiviral drugs used in ophthalmology. Surv Ophthalmol. 1992;37:19-53.
61. Coster D, McKinnon J, McGill J, et al. Clinical evaluation of adenine arabinoside and trifluorothymidine in the treatment of corneal ulcers caused by herpes simplex virus. J Infect Dis. 1976;133(suppl A):173-177.
62. Coster D, Wilhelmus K, Michaud R, et al. A comparison of acyclovir and idoxuridine as treatment for ulcerative herpetic keratitis. Br J Ophthalmol. 1980;64:763.
63. Pavan-Langston D, Buchanan R. Vidarabine therapy of simple and IDU-complicated herpetic keratitis. Trans Am Acad Ophthalmol Otolaryngol. 1976;81:OP813.
64. Pavan-Langston D, Foster C. Trifluorothymidine and idoxuridine therapy of ocular herpes. Am J Ophthalmol. 1977;84:818.
65. Fardeau C, Langlois M, Nugier F, et al. Cross-resistances to antiviral drugs of IUdR-resistant HSV-1 in rabbit keratitis and in vitro. Cornea. 1993;12:19-24.
66. Shearer D, Bourne W. Severe ocular anterior segment ischemia after long-term trifluridine treatment for presumed herpetic keratitis. Am J Ophthalmol. 1990;109:346.
67. Langston R, Pavan-Langston D, Dohlman C. Antiviral medication and corneal wound healing. Arch Ophthalmol. 1974;92:509.
68. Lass J, Langston R, Foster C, et al. Antiviral medications and corneal wound healing. Antiviral Res. 1984;4:143.
69. Barney N, Foster C. A prospective randomized trial of oral acyclovir following penetrating keratoplasty for herpes. Cornea. 1994;13:232-236.
70. Colin J, Robinet A, Malet F. Traitement preventif des keratites herpetiques par l'acyclovir en comprimes. J Fr Ophthalmol. 1993;16:6-9.
71. Collum L, Benedict-Smith A, Hillary I. Randomized double-blind trial of acyclovir and idoxuridine in dendritic corneal ulceration. Br J Ophthalmol. 1980;64:766.
72. Laibson P, Pavan-Langston D, Yeakley W, et al. Acyclovir and vidarabine for the treatment of herpes simplex keratitis. Am J Med. 1982;73:281.
73. Pavan-Langston D, Lass J, Hettinger M, et al. Acyclovir and vidarabine in the treatment of ulcerative herpes simplex keratitis. Am J Ophthalmol. 1981;92:829.
74. Laymann-Simon A, Pavan-Langston D. Long-term oral acyclovir therapy: effect on recurrent infectious herpes simplex keratitis in patients with and without grafts. Ophthalmology. 1996;103:1399-1405.
75. Hovding G. A comparison between acyclovir and trifluorothymidine ophthalmic ointment in the treatment of epithelial herpetic keratitis. Acta Ophthalmol. 1989;67:51-54.
76. La Lau C, Oosterhuis J, Versteeg J, et al. Acyclovir and trifluorothymidine in herpetic keratitis-a multicenter trial. Br J Ophthalmol. 1982;66:506-508.
77. Collum L, Akhtar J, McGettrick P. Oral acyclovir in herpetic keratitis. Trans Ophthalmol Soc U K. 1985;104:629.
78. Hung S, Patterson A, Rees P. Pharmacokinetics of oral acyclovir (Zovirax) in the eye. Br J Ophthalmol. 1984;68:192-195.
79. Schwab I. Oral acyclovir in the management of herpes simplex ocular infections. Ophthalmol. 1988;95:423.
80. Goldberg L, Kaufman R, Kurtz T, et al. Continuous five-year treatment of patients with frequently recurring genital herpes simplex virus infection with acyclovir. J Med Virol. 1993;1:45-50.
81. Mindel A. Long-term clinical and psychological management of genital herpes. J Med Virol. 1993;1:39-44.
82. Fife K, Crumpacker C, Mertz G, et al. Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis. 1994;l69:1338-1341.
83. Spruance S, Stewart J, Rowe N, et al. Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis. 1990;161:185.
84. Manka R. Exogenous lactase in the treatment of oral acyclovir intolerance. Am J Ophthalmol. 1989;108:733.
85. Boyd M, Safrin S, Kern E. Penciclovir: a review of spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem Chemother. 1993;4(suppl 1):25-36.
86. Vere Hodge R, Cheng Y-C. The mode of action of penciclovir. Antiviral Agents Chemother. 1993;4(suppl 1):13-24.
87. Diaz-Mitoma F, Ruben M, Sacks S, et al. Detection of viral DNA to evaluate outcome of antiviral treatment of patients with recurrent genital herpes. J Clin Microbiol. 1996;34:657-663.
88. Cirelli R, Herne K, McCrary M, et al. Famciclovir: review of clinical efficacy and safety. Antiviral Res. 1996;29:141-151.
89. Mertz G, Eron L, Kaufman R, et al. Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection. Am J Med. 1988;85:14-19.
90. Weller S, Blum M, Smiley M. Phase I pharmacokinetics of the acyclovir prodrug, valacyclovir. Antivir Res. 1993;20(suppl 1):144.
91. Pepose J. The potential impact of varicella vaccine and new antivirals on ocular disease related to varicella-zoster virus. Am J Ophthalmol. 1997;123:243-249.
92. Bodsworth N, Crooks R, Borelli S, et al. Valacyclovir versus acyclovir in patient initiated treatment of recurrent genital herpes. Genitourin Med. 1997;73:110-116.
93. Perry C, Faulds D. Valaciclovir: a review of its antiviral activity, pharmacokinetic properties, and therapeutic efficacy in herpes virus infections. Drugs. 1996;52:754-772.
94. Sacks S, Aoki F, Diaz-Mitoma F, et al. Patient-initiated twice-daily oral famciclovir for early recurrent genital herpes. JAMA. 1996;276:44-49.
95. Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med. 1997;10:343-349.
96. Foster CS. Nonsteroidal anti-inflammatory and immunosuppressive agents. In: Lamberts D, Potter D, eds. Clinical Ophthalmologic Pharmacology. Boston, MA: Little, Brown; 1987:173.
97. Kleinen R. Corticosteroid use in ocular infectious disease. In: Tabbara K, Hyndiuk R, eds. Infections of the Eye. Boston, MA: Little, Brown; 1986:293.
98. Kleinert R, Palmer M. Antiinflammatory agents. In: Tabbara K, Hyndiuk R, eds. Infections of the Eye. 2nd ed. Boston, MA: Little Brown & Co.; 1996:301-322.
99. Pavan-Langston D, Dunkel E. Corticosteroids, immunosuppressive agents, and non-steroidal anti-inflammatory drugs. In: Handbook of Ocular Drug Therapy and Ocular Side Effects of Systemic Drugs. Boston, MA: Little, Brown; 1991:182.
100. Taravella MJ, Forstot SL. Calcific band keratopathy. Arch Ophthalmol. 1991;109:1072.
101. Pavan-Langston D. Band keratopathy secondary to herpes simplex or topical corticosteroid [letter]. Arch Ophthalmol. 1994;112:579.
102. Barron BA, Gee L, Hauck WW, et al. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology. 1994;101:1871-1882.
103. Wilhelmus K, Gee L, Hauck WW, et al. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology. 1994;101:1883-1896.
104. Sanitato J, Asbell P, Varnell E, et al. Acyclovir in the treatment of herpetic stromal disease. Am J Ophthalmol. 1984;98:537.
105. Hedshed SG. A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with herpes simplex virus epithelial keratitis. Arch Ophthalmol. 1997;115:703-712.
106. Lairson DR, Begley CE, Wilhelmus KR. Prevention of herpes simplex virus eye disease. A cost benefit analysis. Arch Ophthal. 2003;121:108-112.
107. Ahonen R, Vannas A. Clinical comparison between herpes simplex and herpes zoster ocular infections. In: Maudgal P, Missotten L, eds. Herpetic Eye Diseases. Dordrecht, The Netherlands: Fr. W. Junk; 1985:389.
108. Pavan-Langston D, McCulley J. Herpes zoster dendritic keratitis. Arch Ophthalmol. 1973;89:25.
109. Kodama T, Hayasaka S, Setogawa T. Immunofluorescent staining and corneal sensitivity in patients suspected of having herpes simplex keratitis. Am J Ophthalmol. 1992;113:187.
110. Baum J. Morphogenesis of the dendritic figure in herpes simplex keratitis: a negative study. Am J Ophthalmol. 1970;70:722. .
111. Wu X, Chen X. Acyclovir for the treatment and prevention of recurrent infectious herpes simplex keratitis. Chin Med J (Engl). 2002;115:1569-1572.
112. Cavanagh H. Herpetic ocular disease: therapy of persistent epithelial defects. Int Ophthalmol Clin. 1975;15:67.
113. Kaufman H. Epithelial erosion syndrome: metaherpetic keratitis. Am J Ophthalmol. 1964;57:983.
114. VanBijsterveld O, deKoning E. Trophic herpetic corneal ulcers. In: Blodi F, ed. Herpes Simplex Infections of the Eye. New York, NY: Churchill Livingstone; 1984:29.
115. Kaufman H, Uotila M, Gasset A, et al. The medical uses of soft contact lenses. Trans Am Acad Ophthalmol Otolaryngol. 1971;75:361.
116. Lass J, Berman M, Campbell R, et al. Treatment of experimental herpetic interstitial keratitis with medroxyprogesterone. Arch Ophthalmol. 1980;98:520.
117. Refojo M, Dohlman C, Koliopoulos J. Adhesives in ophthalmology: a review. Surv Ophthalmol. 1971;15:217.
118. Jones B, Falcon M, Williams H, et al. Symposium on herpes simplex eye disease: objectives in therapy. Trans Ophthalmol Soc U K. 1977;97:305.
119. Meyers-Elliott R, Pettit T, Maxwell W. Viral antigens in the immune ring of Herpes simplex stromal keratitis. Arch Ophthalmol. 1980;98:897.
120. Meyers-Elliott RH, Elliott JH, Maxwell WA, et al. HLA antigens in herpes stromal keratitis. Am J Ophthalmol. 1980;89:54.
121. Cohen E, Laibson P, Arentsen J. Corneal transplantation for herpes simplex keratitis. Am J Ophthalmol. 1983;95:645.
122. Langston R, Pavan-Langston D, Dohlman C. Penetrating keratoplasty for herpetic keratitis: prognostic and therapeutic determinants. Trans Am Acad Ophthalmol Otolaryngol. 1975;79:577.
123. Weiss N, Jones B. Problems of corneal grafting in herpetic keratitis. Ciba Found Symp. 1973;15:220.
124. Pepose J. Herpes simplex keratitis: role of viral infection versus immune response. Survey Ophthalmol. 1991;35:345-352.
125. Sundmacher R, Neumann-Haefelin D. Herpes simplex virus isolations from the aqueous of patients suffering from focal iritis, endotheliitis, and prolonged disciform keratitis with glaucoma. Surv Ophthalmol. 1981;27:342.
126. Sutcliffe E, Baum J. Acute idiopathic corneal endotheliitis. Ophthalmol. 1984;91:1161.
127. Sundmacher R, Neumann-Haefelin D. Herpes simplex virus isolation from the aqueous of patients suffering from focal iritis, endotheliitis and prolonged disciform keratitis with glaucoma. Klin Monatsbl Augenheilkd. 1979;175:488.
128. Tullo A, Easty D, Shimeld C, et al. Isolation of herpes simplex virus from corneal discs of patients with chronic stromal keratitis. Trans Ophthalmol Soc U K. 1985;104:159.
129. Jonas JB, Rank RM, Budde WM. Visual outcome after allogenic penetrating keratoplasty. Graefes Arch Clin Ophthalmol. 2002;240:302-307.
130. Robin J, Stergner J, Kaufman H. Progressive herpetic corneal endotheliitis. Am J Ophthalmol. 1985;100:336.
131. Vannas A, Ahonen R. Herpetic endothelial keratitis. Acta Ophthalmol. 1981;59:296.
132. Cheng C, Chang S, Hu F. Acyclovir treatment for linear endotheliitis on grafted corneas. Cornea. 1995;14:311-315.
133. Ohashi Y, Yamamoto S, Nishida K, et al. Demonstration of herpes simplex virus DNA in idiopathic corneal endotheliopathy. Am J Ophthalmol. 1991;112:419-423.
134. Pavan-Langston D, Brockhurst R. Herpes simplex panuveitis: a clinical report. Arch Ophthalmol. 1969;81:783.
135. Pavan-Langston D, Dohlman C, Geary P, et al. Intraocular penetration of Ara A and IDU-therapeutic implications in clinical herpetic uveitis. Trans Am Acad Ophthalmol Otolaryngol. 1973;77:OP 455.
136. Collin H, Abelson M. Herpes simplex virus in human cornea, retro corneal fibrous membrane and vitreous. Arch Ophthalmol. 1976;94:1726.
137. Sundmacher R. A clinico-virologic classification of herpetic anterior segment disease with special reference to intraocular herpes. In: Sundmacher R, ed. Herpetic Eye Disease. Munich: J F Bergmann Verlag; 1981:203.
138. Peek R, Verjans GMGM, Meek B. Herpes simplex virus infection of the human eye induces a compartmentalized virus specific B cell response. J Infect Dis. 2002;186:1539-1546.
139. Nimura M, Nishikawa T. Treatment of eczema herpeticum with oral acyclovir. Am J Med. 1988;85:49-54.
140. Novelli V, Atherton D, Marshall W. Eczema herpeticum. Clin Pediatr. 1988;27:231-234.
141. Pepose JS. External ocular herpesvirus infections in immunodeficiency. Curr Eye Res. 1991;10(suppl):87-95.
142. Binder P. Review of treatment of ocular herpes simplex infections in the neonate and immunocompromised host. Cornea. 1985;3:178.
143. Young T, Robin J, Holland G, et al. Herpes simplex keratitis in patients with acquired immune deficiency syndrome. Ophthalmol. 1989;96:1476.
144. Liekfeld A, Jaeckel C, Pleyer U, et al. [Analysis of the aqueous humor in keratoplasty patients with keratitis. Initial results.] Ophthalmologe. 2001;98:456-459.
145. Kaplan MH, Sadick N, McNutt NS, et al. Dermatologie findings and manifestations of acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol. 1987;16:485-506.
146. Leyden J, Baker B. Localized herpes simplex infections in atopic dermatitis. Arch Dermatol. 1979;115:311-314.
147. Margolis T, Ostler B. Treatment of ocular disease in eczema herpeticum. Am J Ophthalmol. 1990;110:274.
148. Vestey J, Howie S, Norval M, et al. Immune responses to herpes simplex virus in patients with facial herpes simplex and those with eczema herpeticum. Br J Dermatol. 1988;118:775-779.
149. Garrity J, Liesegang T. Ocular complications of atopic dermatitis. Can J Ophthalmol. 1984;19:21.
150. Wilhelmus K, Falcon M, Jones B. Bilateral herpetic keratitis. Br J Ophthalmol. 1981;65:385.
151. Souza PM, Holland EJ, Huang AJ. Bilateral herpetic keratoconjunctivitis. Ophthalmology. 2003;110:493-496.
152. Mines J, Kaplan H. Acquired immune deficiency syndrome (AIDS): the disease and its ocular manifestations. Int Ophthalmol Clin. 1986;26:73-85.
153. Schuman J, Orellana J, Friedman A, et al. Acquired immune deficiency syndrome. Surv Ophthalmol. 1987;31:384-395.
154. Hodge W, Margolis T. Herpes simplex virus keratitis among patients who are positive or negative for human immunodeficiency virus. Ophthalmology. 1997;104:120-124.
155. Rosenwasser G, Greene W. Simultaneous herpes simplex types 1 and 2 keratitis in acquired immune deficiency syndrome. Am J Ophthalmol. 1992;113:102-103.
156. Hodge W, Seiff S, Margolis T. Ocular opportunistic infection incidences among patients who are HIV positive compared to patients who are HIV negative. Ophthalmol. 1998;105:895-900.
157. Temesgen Z, Wright A. Recent advances in the management of human immunodeficiency virus infection. Mayo Clin Proc. 1997;72:854-859.
158. Corey L, Holmes K. Therapy for human immunodeficiency virus infection-what have we learned? N Engl J Med. 1996;335:1142-1144.
159. Ramos-Gomez F, Greenspan D, Oleske J. Pediatric HIV: orofacial manifestations. In: Oleske J, Denny T, eds. Proceedings of the Pediatric HIV Forum; 1994; Newark, NJ: 1-5.
160. Balfour H. Resistance of herpes simplex to acyclovir. Ann Int Med. 1983;98:404.
161. Hirsch MS, Schooley RT. Resistance to antiviral drugs: the end of innocence. N Engl J Med. 1989;320:313-314.
162. Jacobson MA, Berger TG, Fikrig S, et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Int Med. 1990;112:187-191.
163. Ehrlich K, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immune deficiency syndrome. N Engl J Med. 1989;320:293.
164. Sonkin P, Baratz K, Frothingham R, et al. Acyclovir-resistant herpes simplex virus keratouveitis after penetrating keratoplasty. Ophthalmology. 1992;99:1805-1808.
165. Safrin S, Elbeik T, Mills J. A rapid screen test for in vitro susceptibility of clinical herpes simplex virus isolates. J Infect Dis. 1994;169:879-882.
166. Minkovitz J, Pepose J. Topical interferon alpha-2A treatment of herpes simplex keratitis resistant to multiple antiviral medications in an immunosuppressed patient. Cornea. 1995;14:326-330.
167. Ficker L, Kirkness C, Rice N, et al. Changing management and improved prognosis for corneal grafting and herpes simplex keratitis. Ophthalmol. 1989;96:1587.
168. Epstein R, Seedor J, Dreizen N, et al. Penetrating keratoplasty for herpes simplex keratitis and keratoconus: allograft rejection and survival. Ophthalmology. 1987;94:935-944.
169. Rapuano C, Cohen E, Brady SJ, et al. Indications for and outcomes of repeat penetrating keratoplasty. Am J Ophthalmol. 1990;109:689-695.
170. Cleator G, Klapper P, Dennett C, et al. Corneal donor infection by herpes simplex virus: herpes simplex virus DNA in donor corneas. Cornea. 1994;13:294-304.
171. Fine M, Cignetti F. Penetrating keratoplasty in herpes simplex keratitis. Arch Ophthalmol. 1977;95:1755.
172. Mathers W, Jester J, Lemp M. Return of human corneal sensitivity after penetrating keratoplasty. Arch Ophthalmol. 1988;106:210-211.
173. De Kesel RJ, Koppen C, Leven M, et al. Primary graft failure caused by herpes simplex virus type 1. Cornea. 2001;20:187-190.
174. Mannis M, Plotnik R, Schwab I, et al. Herpes simplex dendritic keratitis after keratoplasty. Am J Ophthalmol. 1991;111:480-484.
175. Cobo L, Coster D, Rice N, et al. Prognosis and management of corneal transplantation for herpetic keratitis. Arch Ophthalmol. 1980;98:1755.
176. Rice N, Jones B. Problems of corneal grafting in herpetic keratitis. In: Jones B, ed. Corneal Graft Failure. Ciba Foundation Symposium 15. Amsterdam: Elsevier; 1973:221.
177. Boisjoly H, Roy R, Dube I, et al. HLA-A, B and DR matching in corneal transplantation. Ophthalmology. 1986;93:1290.
178. Davidorf JM. Herpes simplex keratitis after LASIK [letter]. J Refract Surg. 1998;14:667.
179. Perry HD, Doshi S, Cameron CD. Herpes simplex reactivation following laser in situ keratomileusis and subsequent corneal perforation. CLAO J. 2002;28:69-71.
180. Blyth W, Hill T, Field H, et al. Reactivation of herpes simplex virus infection by ultraviolet light and possible involvement of prostaglandins. J Gen Virol. 1976;33:547.
181. Baringer J. The virology of herpes simplex virus infection in humans. Surv Ophthalmol. 1976;21:171.
182. Klein R. Pathogenic mechanisms of recurrent herpes simplex virus infections. Arch Virol. 1976;51:1.
183. Kwon B, Gangarosa L, Burch K, et al. Induction of ocular herpes simplex virus shedding by iontophoresis of epinephrine into rabbit cornea. Invest Ophthalmol. 1981;21:442.
184. Laibson P, Kilbrick S. Reactivation of herpetic keratitis by epinephrine in rabbit. Arch Ophthalmol. 1966;75:254.
185. Nesburn A, Dickenson M, Radnoti M, et al. Experimental reactivation of ocular herpes simplex in rabbits. Surv Ophthalmol. 1976;21:185.
186. Pepose J, Laycock K, Miller J, et al. Reactivation of latent herpes simplex virus by excimer laser photokeratectomy. Am J Ophthalmol. 1992;114:45-50.
187. Vrabec M, Durrie D, Chase D. Recurrence of herpes simplex after excimer laser keratectomy. Am J Ophthalmol. 1992;114:96-97.
188. Akova YA, Onat M, Dauman S. Efficacy of low dose and long term oral Acyclovir therapy after penetrating keratoplasty for herpes simplex keratitis. Ocul Immunol Inflamm. 1999;7:51-60.